Skip to main content

Table 3 Change From Baseline in Mean Monthly Migraine Days by Hormonal Contraception Status

From: Efficacy and safety of erenumab in women with a history of menstrual migraine

  Received Hormonal Contraception Did Not Receive Hormonal Contraception
Placebo
N = 20
Erenumab 70 mg
N = 18
Erenumab 140 mg
N = 27
Placebo
N = 63
Erenumab 70 mg
N = 50
Erenumab 140 mg
N = 54
Monthly migraine days at baseline, mean (SD) 9.5 (3.0) 8.5 (2.7) 8.9 (2.2) 8.3 (2.8) 8.2 (2.3) 8.2 (2.4)
Change from baseline over months 4–6, LSM (95% CI) −1.6 (− 3.4, 0.25) − 2.9 (− 4.8, − 1.0) − 3.9 (− 5.5, − 2.4) − 1.4 (− 2.2, − 0.6) −3.3 (− 4.2, − 2.4) −3.4 (− 4.2, − 2.5)
Difference from placebo   −1.3 (− 3.9, 1.2)
P = 0.3
− 2.4 (− 4.7, − 0.1)
P = 0.045
  −2.0 (− 3.1, − 0.8)
P = 0.001
−2.0 (− 3.1, − 0.8)
P < 0.001
Treatment by subgroup interaction P value over months 4–6 0.76
  1. The analysis included randomized patients who received ≥ 1 dose of investigational product and had ≥ 1 postbaseline measurement during the double-blind treatment phase. Change from baseline in MMD and monthly acute MSMD was analyzed using a generalized linear mixed effects model, which included treatment, visit, treatment by visit interaction, stratification factors (North America/other and naïve/prior use/concomitant use), and baseline value as covariates and assumed a first-order autoregressive covariance structure; missing data were not imputed. P values for pairwise comparisons are nominal P values without multiplicity adjustment
  2. Abbreviations: CI confidence interval, LSM least squares mean